Insider Transactions in Q3 2025 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q3 2025)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 30
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,000
$40.0 P/Share
|
Sep 30
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
Sep 26
2025
|
Cecilia Jones Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,651
-9.73%
|
$131,436
$36.77 P/Share
|
Sep 26
2025
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,472
+16.61%
|
-
|
Sep 05
2025
|
Theodore James Washburn Jr. Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
8,546
-90.78%
|
$307,656
$36.87 P/Share
|
Aug 27
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
200
-1.12%
|
$8,000
$40.0 P/Share
|
Aug 27
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.11%
|
$3,600
$18.09 P/Share
|
Aug 11
2025
|
Cynthia Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
Aug 11
2025
|
Rahul D. Ballal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,302
+15.64%
|
-
|
Aug 08
2025
|
Brian Goff Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,085
-8.23%
|
$399,060
$36.67 P/Share
|
Aug 08
2025
|
Brian Goff Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,691
+14.42%
|
-
|
Jul 10
2025
|
David Scadden Director |
SELL
Open market or private sale
|
Direct |
1,400
-7.37%
|
$56,000
$40.0 P/Share
|
Jul 10
2025
|
David Scadden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,400
+6.86%
|
$25,200
$18.09 P/Share
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,914
-8.24%
|
$452,732
$38.34 P/Share
|
Jul 09
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,914
+14.0%
|
$297,850
$25.01 P/Share
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,091
-6.26%
|
$139,094
$34.17 P/Share
|
Jul 01
2025
|
Sarah Gheuens Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,374
+11.36%
|
-
|